MUMBAI, April 17 (Reuters) - Agila Biotech, a unit of Indian drugmaker Strides Arcolab, and U.S.-based Pfenex Inc will develop and commercialise six biosimilars for global markets through a joint venture, the two companies said in a statement.
Agila Biotech will hold a 51 percent stake in the venture, but both parties will have equal say regarding product development and commercialisation, they said late on Tuesday.
Our Standards: The Thomson Reuters Trust Principles.